SKF presents scalable clean technologies and circular solutions at COP30; wins SBCOP's Best Cases
SKF makes remanufacturing work globally - Winner of SBCOP's Best Cases GOTHENBURG, Sweden, Nov. 10, 2025 /PRNewswire/ -- At COP30 in Belem, Brazil, SKF will showcase scalable clean technologies and circular solutions to accelerate industrial...
OCBC Launches Tap Credit Card: Seamless NFC Transactions for Speed and Convenience
JAKARTA, Indonesia, Nov. 10, 2025 /PRNewswire/ -- PT Bank OCBC NISP Tbk (OCBC) today officially announced the launch of its Tap Credit Card, an innovative contactless payment service that enables customers to make transactions simply by tapping...
Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo
BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that...
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in...
Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech
BEIJING, Nov. 10, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng...
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)
SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for...
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as...
DFRobot UNIHIKER K10 Crowned Winner in Teach Secondary's EdTech & Software Category at 2025 TeachCo Resource Awards
SHANGHAI, Nov. 10, 2025 /PRNewswire/ -- DFRobot is proud to announce that its UNIHIKER K10 has received the top honor in the "Teach Secondary's EdTech & Software" category at the prestigious 2025 TeachCo Resource Awards. DFRobot UNIHIKER K10...